Home Biosimilar Antibodies Others Others Axatilimab (Anti-CSF1R / M-CSFR / CD115)
For research use only. Not for use in humans.

Axatilimab (Anti-CSF1R / M-CSFR / CD115)

Synonyms: SNDX-6352

Axatilimab (Anti-CSF1R / M-CSFR / CD115) is a humanized IgG4 antibody targeting CSF-1R. It can be used for the research of chronic graft versus host disease (cGVHD) and neoplastic diseases. MW :141.3 KD.

Axatilimab (Anti-CSF1R / M-CSFR / CD115)

Quality Control

Batch: A311701 Purity: 99% Protein concentration: Endotoxin Level:
99

Mechanism of Action

Description
Axatilimab (Anti-CSF1R / M-CSFR / CD115) is a humanized IgG4 antibody targeting CSF-1R. It can be used for the research of chronic graft versus host disease (cGVHD) and neoplastic diseases. MW :141.3 KD.
References

Product Details

CAS No. 2155851-88-8
Isotype Human IgG4SP
Source CHO
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07015853 NOT_YET_RECRUITING Drug: Pembrolizumab|Drug: Axatilimab TNBC - Triple-Negative Breast Cancer; Breast Cancer Stephen Shiao 2026-06 PHASE2
NCT07128381 RECRUITING Drug: Axatilimab (SNDX-6352)|Drug: Ruxolitinib Myelofibrosis (MF); Chronic Myelomonocytic Leukemia (CMML) M.D. Anderson Cancer Center 2026-01-02 PHASE1; PHASE2
NCT06663722 RECRUITING Chronic Graft Versus Host Disease; cGVHD University of Miami 2025-05-05 PHASE2
NCT07511062 NOT_YET_RECRUITING Drug: Decitabine|Drug: Venetoclax|Drug: Axatilimab Acute Myeloid Leukemia; TP53 Gene Mutation Northside Hospital, Inc. 2026-08-01 PHASE1
NCT07124078 RECRUITING Drug: INCA034176|Drug: Best available Treatment (BAT) Chronic Graft-versus-host-disease Incyte Corporation 2026-05-20 PHASE2
NCT07638982 NOT_YET_RECRUITING Drug: Axatilimab Diffuse Large B Cell Lymphoma (DLBCL); Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma; High-grade B-cell Lymphoma (HGBCL); High-Grade B-Cell Lymphoma, Nos; PMBCL; Follicular Grade 3 Lymphoma Northside Hospital, Inc. 2026-10-31 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-04-20)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.